New research highlights the positive impact of glp-1s and other anti-obesity medications on the allurion program

Natick, mass.--(business wire)---- $alur #allurion--allurion technologies, inc. (nyse: alur), a company dedicated to ending obesity, today announced results of research that highlighted the positive impact of the growing interest in anti-obesity medications on allurion program awareness and uptake. the global market for anti-obesity medications – specifically of glp-1s (glucagon-like peptide-1 receptor agonists) – is expected to reach $100 billion by 2030.1 research has shown these products have significantly alte.
ALUR Ratings Summary
ALUR Quant Ranking